Clinical trial
Imatinib Mesylate in Treating Patients With Myelofibrosis
NCT00039416 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039416 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Myelofibrosis |
| Official title | A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 18 |
| Start date | Apr 1, 2002 |
| Primary completion | Aug 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 25, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: